Glucagon-like Peptide (GLP)-1 and Leptin Concentrations in Obese Patients with Type 2 Diabetes Mellitus
Overview
Authors
Affiliations
Aims: To assess differences in circulating leptin and glucagon-like peptide (GLP)-1 concentrations before and after an oral glucose load, in euglycaemic and isoinsulinaemic conditions, between obese patients with and without Type 2 diabetes mellitus.
Methods: Ten male obese (body mass index (BMI) > 30 kg/m2) patients with Type 2 diabetes and 20 matched non-diabetic subjects were studied. Leptin, GLP-1(7-36)amide and GLP-1(7-37) concentrations were measured 0, 30, 60, and 90 min after a 50-g oral glucose load administered 90 min after the beginning of a euglycaemic hyperinsulinaemic clamp.
Results: GLP-1(7-36)amide concentrations before the glucose load were significantly lower in diabetic patients than in controls (median (quartiles): 50.5 (44.7-53.2) vs. 128.7(100-172.5) pg/ml; P < 0.01), while no difference was observed in baseline GLP-1(7-37). In non-diabetic subjects, GLP-1(7-36)amide and GLP-1(7-37) concentrations increased significantly after the oral glucose load, while no glucose-induced increase in GLP-1 concentration was observed in diabetic patients. GLP-1(7-36)amide at 30, 60, and 90 min, and GLP-1(7-37) at 30 min, of the glucose challenge, were significantly lower in diabetic patients. Leptin concentrations were not significantly different in diabetic patients when compared to non-diabetic subjects, and they did not change after the oral glucose load.
Discussion: Leptin concentrations are not significantly modified in obese Type 2 diabetic patients. GLP-1(7-36)amide baseline concentrations are reduced in Type 2 diabetes; moreover, diabetic subjects show an impaired response of GLP-1 to oral glucose in euglycaemic, isoinsulinaemic conditions. This impairment, which is not the result of differences in glycaemia or insulinaemia during assessment, could contribute to the pathogenesis of hyperglycaemia in Type 2 diabetes mellitus.
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders.
Cortes-Martin A, Plaza-Diaz J World J Gastroenterol. 2025; 31(4):101436.
PMID: 39877709 PMC: 11718636. DOI: 10.3748/wjg.v31.i4.101436.
Zhang Q, Liu H, Zhang J, Ouyang Y, Fu X, Xie C Front Pharmacol. 2025; 15():1501990.
PMID: 39845797 PMC: 11752898. DOI: 10.3389/fphar.2024.1501990.
Thomas S, Besecker B, Choe Y, Christofides E Front Clin Diabetes Healthc. 2024; 5:1399410.
PMID: 38903056 PMC: 11188454. DOI: 10.3389/fcdhc.2024.1399410.
Altered chronic glycemic control in a clinically relevant model of rat thoracic spinal contusion.
Harris K, Welch B, Smith A, Pride Y, Grayson B Biosci Rep. 2022; 43(1).
PMID: 36472154 DOI: 10.1042/BSR20221699.
Gut microbes and food reward: From the gut to the brain.
de Wouters dOplinter A, Huwart S, Cani P, Everard A Front Neurosci. 2022; 16:947240.
PMID: 35958993 PMC: 9358980. DOI: 10.3389/fnins.2022.947240.